By Hilary Rosselot
Healx Presents During the 2022 Industry Updates Keynote at the 18th International Fragile X Conference
Wayne Chadwick, a Principal Pharmacologist at Healx Ltd., presented about the IMPACT-FXS trial during the Industry Updates keynote session at the 18th International Fragile X Conference.
IMPACT-FXS is a Phase 2 trial targeting multiple pathways associated with Fragile X to maximize the number of behaviors treated in individuals with Fragile X syndrome.
Wayne shared more about Healx, their novel AI approach to finding treatments, and their Phase 2 trial. Learn more about Healx and the IMPACT-FXS trial by watching their 2022 Industry Updates presentation or vising their MyFXResearch post.
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
CRISPR, a New Genome Editing Tool: Could it Work for Fragile X-Associated Syndromes?
Each year, the National Fragile X Foundation funds one or more summer student research fellowships at $2,500 each through the Summer Student Fellowship Research Fund [Note: now the Randi J. Hagerman Summer Scholar Research [...]
Rockefeller University: Potential new treatment for Fragile X targets one gene to affect many
Above: Mouse brains with Fragile X Syndrome (lower) lose the ability to regulate proteins like Brd4 (green). Photo from The Rockefeller University. A new publication in the journal Cell describes efforts by two groups at Rockefeller [...]